Trial Profile
A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL 23p19 Risankizumab Compared to FUMADERM in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate; Dimethyl fumarate
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 01 Aug 2021 Results assessing the patient-reported outcome PROs with risankizumab vs. fumaric acid esters at weeks 0, 16 and 24, published in the Journal of the European Academy of Dermatology and Venereology.
- 15 May 2021 Results assessing comparison of efficacy and safety of risankizumab treatment with fumaric acid esters in moderate to severe plaque psoriasis patients, published in the British Journal of Dermatology.
- 13 Jul 2018 Status changed from active, no longer recruiting to completed.